Roche at EBCC 2018
The 11th European Breast Cancer Conference provided a multidisciplinary setting for breast cancer specialists from around the world.
Mar 20, 2018 | Breast CancerMar 20, 2018 | Breast Cancer
In Switzerland, physicians can treat patients with unlicensed adjuvant pertuzumab through a special access mechanism by Swiss law (KVV71 a/b). This poster describes the experience of 12 patients treated with adjuvant pertuzumab, before the publication of APHINITY trial’s results, in the real-world setting in Switzerland. Patients treated with adjuvant pertuzumab between July 2015 and March 2017 at three Swiss cancer centers were identified.
Mar 21, 2018 | Breast Cancer
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 programMar 21, 2018 | Breast Cancer
The UmbHER1 study assessed the safety and tolerability of subcutaneous (SC) Herceptin in patients with early (EBC) or metastatic breast cancer (MBC) treated with or without concurrent chemotherapy or pertuzumab. A pooled analysis of safety data from the 5 EBC and 2 MBC studies included in the UmbHER1 umbrella program is presented.